AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Protara Therapeutics, Inc. Director's Dealing 2016

Oct 20, 2016

34057_dirs_2016-10-20_86495e6c-308d-4e86-ab42-a91e84f1dfcf.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2016-10-18

Reporting Person: HASTINGS PAUL J (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value	6636	Indirect

Footnotes

F1: The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012.